Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. (2nd July 2020)

• Record Type: Journal Article
• Authors: Slentz, Dane H.; Nelson, Christine C.; Smith, Terry J.
• Is Part Of: Expert opinion on investigational drugs. Volume 29:Number 7(2020)
• Page Start: 645
• Page End: 649
• Publication Date: 2020-07-02
• Subjects: IGF-IR -- Graves' disease -- thyroid-associated ophthalmopathy -- thyroid eye disease -- R1507 -- RV001 -- teprotumumab -- Tepezza; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2020.1772752
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: Thyroid-associated ophthalmopathy (TAO) is a disfiguring, potentially blinding, and sub-optimally managed autoimmune condition. Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in two clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO. Areas covered: This article reviews phase II and III placebo-controlled, double-masked, prospective, multicenter studies assessing the efficacy and safety of teprotumumab for the treatment of active, moderate-to-severe TAO. Expert opinion: Teprotumumab has demonstrated substantial and rapid improvement in Clinical Activity Score and proptosis reduction in TAO compared to placebo. Subjective diplopia and quality of life were also improved in both clinical trials. Teprotumumab exhibited a favorable safety profile, with transient hyperglycemia, muscle cramps, and auditory side effects being associated with the drug; these were usually transient. The trial findings indicate that teprotumumab is a promising, potential first-line therapy for treating TAO.